65,437 trials
Cutaneous T-Cell Lymphoma
Primary: Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion…
Diabetic Kidney Disease
Primary: The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure. — 458…
Autoimmune Pulmonary Alveolar Proteinosis
Primary: Absolute Change From Baseline of Alveolar-arterial Oxygen Concentration (A-a(DO2)) After 24 Weeks of Treatment — 28.6; 29.3; 32.0 mmHg — p=0.1688
Breast Neoplasms
Primary: Part I Only: Clinical Benefit Rate (CR+PR+SD≥6months) of Patients Who Received Neratinib Alone — 5 Participants
Hypertension
Primary: Blood Pressure at 6 Months — 135.0; 132.3; 85.6; 85.1 mmHG
Alcohol Use Disorder
Primary: Total Number of Standard Drinks Per Day Consumed During Natural (Usual Environment) Conditions — 6.018; 3.534; 3.998; 5.012 standard drinks per day — p=0.013
Neutropenia
Primary: Duration of Severe Neutropenia (DSN) in Cycle 1 — 1.03; 0.44; 0.03; 0.31 days — p=0.296
Graft-versus-host Disease (GVHD)
Primary: Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host…
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
Primary: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical Coronavirus Disease (COVID-19) With Seronegative Status With Onset at…
Stroke · Hemiparesis
Primary: Cortical Excitability MEP Amplitude (µV) — 325 µV
Intraocular Melanoma · Melanoma (Skin)
Primary: Percentage of Participants With Immune-related Adverse Events (irAEs) — 80.0; 72.0; 65.4 Percentage of participants
Sickle Cell Disease
Primary: Number Of Participants With Treatment-emergent Adverse Events (TEAEs) And Serious Adverse Events (SAEs) — 12; 24; 18; 23 Participants
Colorectal Cancer
Primary: Number of Participants With Treatment Related Adverse Events — 0; 0 Participants
Enterovirus · Rhinovirus
Primary: Time From First Dose to Symptom Response Over 21 Days of Follow up Based Upon the FLU-PRO Instrument (Novel Endpoint) — 122.5; 137.1 hours — p=0.4009
Type 2 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -2.37; -2.55; -2.82; -1.29 percentage of HbA1c — p=<0.001